Crinetics Pharmaceuticals, Inc. (CRNX) | Investment Case

1. Company Snapshot

1.a. Company Description

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors.Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases.

Crinetics Pharmaceuticals, Inc.was incorporated in 2008 and is headquartered in San Diego, California.

Show Full description

1.b. Last Insights on CRNX

Breaking News: Crinetics Pharmaceuticals Inc reported a Q4 loss of $1.29 per share beating estimates of $1.37 loss. This compares to a loss of $0.88 per share in the same quarter last year. The company reported its Q4 2025 earnings and held an earnings call. Analysts recommendations are mixed with some analysts recommending a buy and others a hold. For example one analyst from a top firm gave a buy rating. Several firms also reaffirmed their hold ratings.

1.c. Company Highlights

Last Price	40.12
Change Percentage	-1.38%
Open	39.67
Previous Close	40.68
Market Cap ( Millions)	4113
Volume	958686
Year High	57.99
Year Low	24.1
M A 50	48.59
M A 200	39.2

FCF Yield	-9.33%
Dividend Yield	0.00%
ROE	-41.46%
Debt / Equity	4.89%
Net Debt / EBIDTA	10.56%
Price To Book	3.8
Price Earnings Ratio	-8.11
Price To FCF	-10.72
Price To sales	758.81
EV / EBITDA	-8.09

2. Crinetics Pharmaceuticals' 2025 Earnings: A Breakout Year

Crinetics Pharmaceuticals reported a total net revenue of $6.2 million for the fourth quarter of 2025, comprising $5.4 million in net product revenue from Palsonify and $800,000 from a licensing agreement. The company's research and development expenses were $85.1 million, and selling, general, and administrative expenses were $53.7 million. The actual EPS came out at '-1.30575', beating estimates at '-1.37'. The company's cash, cash equivalents, and investments totaled approximately $1.4 billion following a January 2026 public offering, providing a significant runway to execute on commercialization and clinical trials.

Publication Date: Mar -01

                                    📋 Highlights
                                    Palsonify Commercial Launch Progress:
                                                Over 200 enrollment forms received in Q4 2025, with more than 125 unique prescribers adopting the treatment.
2025 Financial Performance:
                                                Q4 2025 net revenue reached $6.2M, including $5.4M in Palsonify product revenue and $800K from a licensing agreement.
Cash Position and Runway:
                                                Ended 2025 with $1.4B in cash after a January 2026 public offering, funding operations until 2030 despite $326.2M in annual cash burn.
Phase 2/3 Trial Initiation:
                                                Plans to launch the global Equilibrium ADCS study for atumelanant in Cushing’s disease by mid-2026 following promising Phase 2 results.

                                

Pipeline Progress

The company's pipeline includes several late-stage candidates, including paltusotine for carcinoid syndrome and congenital adrenal hyperplasia (CAH), and atumelanant for CAH and Cushing's disease. Atumelanant has shown promising results in Phase 2 studies for Cushing's disease, with rapid and sustained reductions in cortisol levels. The company will initiate an operationally seamless global Phase 2/3 study, Equilibrium ADCS, in the first half of 2026. As per the management, they expect to communicate Phase 2 results for the BRAVEST trial at a scientific conference, aiming to motivate investigators and patients to participate in Phase 3.

Palsonify Launch Update

Regarding the launch of Palsonify, the company reported 200 enrollment forms in Q4 and is pleased with the uptake. Payer dynamics for Palsonify are progressing well, with most coverage already in place and prior authorizations proceeding smoothly. The company expects the cadence of the launch to be lumpy but is working to become the number one acromegaly treatment.

Valuation Metrics

The company's P/S Ratio stands at 777.35, indicating a high revenue multiple. The EV/EBITDA ratio is -8.29, reflecting the company's current loss-making status. With the expected revenue growth at 184.8% next year, the current valuation may be justified if the company continues to execute on its commercialization and clinical trials. The ROE and ROIC are -41.46% and -49.33%, respectively, highlighting the company's current investment phase.

Future Outlook

The company expects GAAP operating expenses to be around $606 million and non-GAAP operating expenses between $480 million and $520 million. The increased operating expenses are due to ongoing investments in clinical trials and commercialization activities for Palsonify. Crinetics Pharmaceuticals believes its existing cash and investments will fund operations until 2030, providing a significant runway to execute on commercialization and clinical trials.

3. NewsRoom

Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript

Feb -27

Source: seekingalpha.com

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates

Feb -27

Source: zacks.com

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb -26

Source: globenewswire.com

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of “Moderate Buy” by Analysts

Feb -07

Source: defenseworld.net

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

Feb -05

Source: globenewswire.com

Critical Review: Xenetic Biosciences (NASDAQ:XBIO) & Crinetics Pharmaceuticals (NASDAQ:CRNX)

Jan -30

Source: defenseworld.net

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Jan -26

Source: globenewswire.com

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Jan -22

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.43%)

6. Segments

Novel Therapeutics

Expected Growth: 10.43%

Crinetics Pharmaceuticals' Novel Therapeutics segment growth is driven by increasing adoption of its pipeline of novel, oral somatostatin agonists for rare endocrine disorders, strong clinical trial results, and strategic partnerships. The company's focus on rare diseases with high unmet needs, combined with its innovative approach, positions it for continued growth.

7. Detailed Products

Parsaclisib

An oral, selective inhibitor of the MALT1 protease, being developed for the treatment of hematologic malignancies, including mantle cell lymphoma and diffuse large B-cell lymphoma.

CRN0477

An oral, non-peptide somatostatin receptor subtype 5 (SST5) agonist, being developed for the treatment of congenital hyperinsulinism and endocrine disorders.

CRN0481

An oral, non-peptide ACTH antagonist, being developed for the treatment of Cushing's disease and other disorders related to excess ACTH production.

CRN0491

An oral, non-peptide melanocortin receptor 1 (MC1R) agonist, being developed for the treatment of inflammatory disorders, including vitiligo.

8. Crinetics Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Crinetics Pharmaceuticals, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for the diseases it targets.

Bargaining Power Of Customers

Crinetics Pharmaceuticals, Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternatives.

Bargaining Power Of Suppliers

Crinetics Pharmaceuticals, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and services.

Threat Of New Entrants

Crinetics Pharmaceuticals, Inc. has a high threat of new entrants due to the growing interest in biotechnology and pharmaceuticals, making it easier for new companies to enter the market.

Intensity Of Rivalry

Crinetics Pharmaceuticals, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	8.76%
Debt Cost	3.95%
Equity Weight	91.24%
Equity Cost	7.12%
WACC	6.84%
Leverage	9.60%

11. Quality Control: Crinetics Pharmaceuticals, Inc. passed 3 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

SpringWorks Therapeutics

A-Score: 4.3/10

Value: 6.2

Growth: 4.6

Quality: 5.0

Yield: 0.0

Momentum: 8.0

Volatility: 2.0

1-Year Total Return ->

Avidity Biosciences

A-Score: 4.2/10

Value: 6.2

Growth: 2.7

Quality: 5.1

Yield: 0.0

Momentum: 10.0

Volatility: 1.3

1-Year Total Return ->

Cytokinetics

A-Score: 4.0/10

Value: 8.0

Growth: 0.4

Quality: 4.9

Yield: 0.0

Momentum: 9.0

Volatility: 1.7

1-Year Total Return ->

Sarepta Therapeutics

A-Score: 3.8/10

Value: 8.7

Growth: 7.9

Quality: 5.1

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

Agios Pharmaceuticals

A-Score: 3.2/10

Value: 7.6

Growth: 4.2

Quality: 5.1

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

Crinetics Pharmaceuticals

A-Score: 2.8/10

Value: 6.4

Growth: 1.1

Quality: 5.1

Yield: 0.0

Momentum: 1.5

Volatility: 2.7

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

19.89%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

6.84%

Crinetics Pharmaceuticals, Inc. - US22663K1079

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on CRNX

1.c. Company Highlights

Strong Momentum

Average Quality

Average Growth

Earnings Miss

Revenues Beats

Revenues Miss

Stable Momentum

Earnings Beats

Weak Momentum

Lower Growth

2. Crinetics Pharmaceuticals' 2025 Earnings: A Breakout Year

Pipeline Progress

Palsonify Launch Update

Valuation Metrics

Future Outlook

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.43%)

6. Segments

Novel Therapeutics

Expected Growth: 10.43%

7. Detailed Products

Parsaclisib

CRN0477

CRN0481

CRN0491

8. Crinetics Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Crinetics Pharmaceuticals, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

40.12$

Current Price

40.12$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA